title: Peripheral autonomic potentials in primary headache and drug-induced headache.
abstract: Autonomic functions of different primary headache types have been investigated in several studies, most of them analyzing cardiovascular reflex mechanisms or biochemical changes. The results are contradictory; only in tension-type headache and in cluster headache has a sympathetic hypofunction been shown in a preponderance of studies. We analyzed the peripheral autonomous potentials (PAPs) in different primary headache types and in drug-induced headache and compared the results with those of healthy subjects and of patients with low back pain. Latencies of PAPs were significantly increased in all headache types but not in low back pain; amplitudes of PAPs did not show significant differences compared to healthy subjects. Patients with a long duration of drug abuse had increased PAP latencies, whereas patients with a high number of migraine attacks per year had decreased latencies. Our data suggest that sympathetic hypofunction as measured by PAP latencies is a general phenomenon in headache but not in all pain syndromes. Drug abuse leads to an increase of this hypofunction. While measuring PAPs is not an appropriate method by which to differentiate between headache disorders, it allows assessment of autonomic disturbances in primary and drug-induced headache.
authors.affiliation: Department of Neurology, University of Münster, Germany. everss@uni-muenster.de
authors.forename: S
authors.initials: S
authors.lastname: Evers
authors.forename: H
authors.initials: H
authors.lastname: Voss
authors.forename: B
authors.initials: B
authors.lastname: Bauer
authors.forename: P
authors.initials: P
authors.lastname: Sörös
authors.forename: I W
authors.initials: IW
authors.lastname: Husstedt
mesh_terms: D000328:Adult; D001341:Autonomic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D001342:Autonomic Nervous System Diseases / Q000175:diagnosis / Q000503:physiopathology; D004878:Ergotamine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006261:Headache / Q000139:chemically induced / Q000503:physiopathology*; D006801:Humans; D017116:Low Back Pain / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000139:chemically induced / Q000503:physiopathology; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology
chemical_list: D004878:Ergotamine